{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:46:31Z","timestamp":1790505991472,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["203120"],"award-info":[{"award-number":["203120"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaad.2018.10.037","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T12:01:26Z","timestamp":1540555286000},"page":"714-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis"],"prefix":"10.1016","volume":"80","author":[{"given":"Kevin","family":"Robbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Maeda-Chubachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Peppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2018.10.037_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.10.037_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.037_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/09546634.2017.1328098","article-title":"Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis","volume":"28","author":"Koo","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.10.037_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.10.037_bib5","first-page":"CD005028","article-title":"Topical treatments for chronic plaque psoriasis","volume":"3","author":"Mason","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.10.037_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"3","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin"},{"key":"10.1016\/j.jaad.2018.10.037_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2018.10.037_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaad.2018.10.037_bib9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.037_bib10","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"issue":"7128","key":"10.1016\/j.jaad.2018.10.037_bib11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2018.10.037_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.10.037_bib13","first-page":"989e1001","article-title":"Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions","volume":"40","author":"Di Meglio","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.037_bib14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/pr.113.007823","article-title":"Aryl hydrocarbon receptor control of adaptive immunity","volume":"65","author":"Quintana","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.037_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.037_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.037_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12 week, multicenter, randomized placebo-controlled, double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.10.037_bib18","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1468-3083.2011.04332.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial","volume":"26","author":"Bissonnette","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.037_bib19","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaad.2018.10.037_bib20","series-title":"DOVONEX (calcipotriene) Cream, 0.005%. Prescribing Information","year":"2015"},{"key":"10.1016\/j.jaad.2018.10.037_bib21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/jid.2012.124","article-title":"Why statistics matter: limited inter-rater agreement prevents using the Psoriasis Area and Severity Index as a unique determinant of therapeutic decision in psoriasis","volume":"132","author":"Gourranud","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.10.037_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.037_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.10.037_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.037_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1185\/03007995.2010.541005","article-title":"Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris","volume":"27","author":"van de Kerkhof","year":"2011","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832807X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832807X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:48:11Z","timestamp":1759272491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221832807X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S019096221832807X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.037","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}